FDA Regulatory, Healthcare Compliance, Market Access and Reimbursement, Privacy

Drug or Beauty Product – Blurring the Lines Creates Compliance Risks

On September 28 of this year, the FDA’s Office of Prescription Drug Promotion (“OPDP”) issued an Untitled Letter to Evolus, Inc. (“Evolus”) concerning promotional materials the company posted on its Instagram page. Evolus is the manufacturer of Jeuveau, a prescription injectable neurotoxin “that temporarily smooths moderate to severe frown lines between the eyebrows.” The FDA […]